<DOC>
	<DOCNO>NCT00225667</DOCNO>
	<brief_summary>The purpose study determine whether irbesartan reduce rate recurrent atrial high rate episode development clinical sustain atrial fibrillation patient hypertension permanent pacemaker .</brief_summary>
	<brief_title>Irbesartan Prevention Atrial Arrhythmias Cardiac Electrical Remodeling Patients With Hypertension Permanent Pacemakers</brief_title>
	<detailed_description>Patients permanent pacemaker high risk atrial fibrillation ( AF ) , particularly hypertension , sinus node dysfunction , short episode atrial arrhythmia , know atrial high-rate episode ( AHRE ) . AHRE felt precursor AF , may result cause chang atrial electrophysiology , structure ( know cardiac remodel ) associate development AF . Evaluating process human AF limit cumbersome nature perform serial , invasive electrophysiologic study . However , modern pacemaker permit rapid , non-invasive electrophysiologic test also accurately document AHRE , allow convenient study therapy aim prevent progression AHRE overt AF . In addition , group patient also afford ability evaluate recurrence AHRE progression structural electrical remodeling . Comparison : Irbesartan compare placebo .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Remodeling</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Sinus Node Dysfunction ( without AV conduction disturbance ) Permanent , atrial dualchamber pacemaker implant &gt; 2 month enrollment ability record store atrial highrate episode , frequency mode switch perform noninvasive electrophysiologic test History least 6 AHRE last 6 month ( rate &gt; 220/min , duration &gt; 2 minute History prior diagnosis hypertension and/or treat hypertension OR two document BP &gt; 130/85 ( measurement do least one week apart ) Permanent persistent AF 6 episode symptomatic paroxysmal AF previous 6 month Documented Cr &gt; 200 umol/L K+ &gt; 5.2 mmol/L previous 3 month Current treatment potassium spar diuretic , unless serum potassium know normal range LV ejection fraction know &lt; 40 % Moderate severe mitral regurgitation ( 3+ , 4 + ) Mitral stenosis mild severity Aortic stenosis mean gradient &gt; 25 mmHg Angina rest last 2 month , current CCS Class 3 4 angina Unipolar atrial lead Previous AV node ablation Pwave amplitude le 1.5 mV Current therapy ACE inhibitor , ARB aldosterone antagonist Current plan ( within 6 month ) antiarrhythmic medication ( amiodarone , sotalol , flecainide , propafenone , quinidine , dofetilide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Pacemaker , Artificial</keyword>
	<keyword>Atrial High Rate Episodes</keyword>
	<keyword>Electrophysiology</keyword>
	<keyword>Renin-Angiotensin System</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Cardiac Remodeling</keyword>
</DOC>